Literature DB >> 25247622

Drug-induced immune hemolytic anemia: the last 30 years of changes.

Patricia A Arndt1.   

Abstract

Drug-induced immune hemolytic anemia (DIIHA) is a rare condition that occurs primarily as a result of drug-induced antibodies, either drug-dependent or drug-independent. Drug- dependent antibodies can be detected by testing drug-treated red blood cells (RBCs) or untreated RBCs in the presence of a solution of drug. Drug-independent antibodies react with untreated RBCs (no drug added) and cannot be distinguished from warm autoantibodies. Many changes have occurred during the last 30 years, such as which drugs most commonly cause DIIHA, the optimal testing methods for identifying them, and the theories behind the mechanisms by which they react. This article reviews the major changes in DIIHA since the early 1980s involving the immune complex mechanism, cephalosporins, nonimmunologic protein adsorption, and penicillins. Because serologic results associated with DIIHA can mimic those expected with autoimmune hemolytic anemia or hemolytic transfusion reactions, DIIHA may go undetected in some cases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25247622

Source DB:  PubMed          Journal:  Immunohematology        ISSN: 0894-203X


  10 in total

1.  Ceftriaxone-Induced Hemolytic Anemia: A Rare Case Report.

Authors:  Sandeep Kumar; Rohit Bansal; Priya Bansal; Rajinder Kumar Dhamija; Dnb Neurology
Journal:  Perm J       Date:  2019-12-18

Review 2.  Pharmacogenomics with red cells: a model to study protein variants of drug transporter genes.

Authors:  Willy Albert Flegel; Kshitij Srivastava; Tristan Michael Sissung; Barry Ronald Goldspiel; William Douglas Figg
Journal:  Vox Sang       Date:  2020-09-30       Impact factor: 2.996

3.  Variability of Findings in Drug-Induced Immune Haemolytic Anaemia: Experience over 20 Years in a Single Centre.

Authors:  Beate Mayer; Thilo Bartolmäs; Salih Yürek; Abdulgabar Salama
Journal:  Transfus Med Hemother       Date:  2015-09-09       Impact factor: 3.747

4.  Case Report: First Case of Cefotaxime-Sulbactam-Induced Acute Intravascular Hemolysis in a Newborn With ABO Blood Type Incompatibility by the Mechanism of Non-Immunologic Protein Adsorption.

Authors:  Yuanjun Wu; Yong Wu; Yong Yang; Baochan Chen; Jianqun Li; Ganping Guo; Fu Xiong
Journal:  Front Immunol       Date:  2021-12-22       Impact factor: 7.561

5.  Case report: First case of pemetrexed plus cisplatin-induced immune hemolytic anemia in a patient with lung adenocarcinoma.

Authors:  Hongkai Lu; Na Wang; Peng Wang; Haolin Zhang; Ru Zhao; Hongju Liu; Xirong He; Zeya Liu; Yue Chang; Yongtong Cao; Shiyao Wang
Journal:  Front Med (Lausanne)       Date:  2022-08-25

6.  Increasing Incidence and Prevalence of Acquired Hemolytic Anemias in Denmark, 1980-2016.

Authors:  Dennis Lund Hansen; Sören Möller; Kjeld Andersen; David Gaist; Henrik Frederiksen
Journal:  Clin Epidemiol       Date:  2020-05-22       Impact factor: 4.790

Review 7.  Ceftriaxone-induced hemolytic anemia with severe renal failure: a case report and review of literature.

Authors:  Hans Benno Leicht; Elke Weinig; Beate Mayer; Johannes Viebahn; Andreas Geier; Monika Rau
Journal:  BMC Pharmacol Toxicol       Date:  2018-10-25       Impact factor: 2.483

8.  Co-Amoxiclav Induced Immune Haemolytic Anaemia: A Case Report.

Authors:  H G C S Karunathilaka; D P Chandrasiri; P Ranasinghe; V Ratnamalala; A H N Fernando
Journal:  Case Rep Hematol       Date:  2020-03-31

9.  Hemolytic Anemia and Reactive Thrombocytosis Associated With Cefoperazone/Sulbactam.

Authors:  Ling Zhou; Jianan Bao; Jingjing Ma
Journal:  Front Pharmacol       Date:  2019-11-08       Impact factor: 5.810

10.  An Uncommon Incidence of Drug-Induced Immune Hemolytic Anemia Secondary to Ceftriaxone.

Authors:  Aishwarya Sharma; Shannon Chamberlain; Devendranath Mannuru; Abhishek Matta
Journal:  Cureus       Date:  2021-12-25
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.